Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SL327 是能通过血脑屏障运输的选择性 MEK1/2 抑制剂,IC50 分别为 0.18 和 0.22 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 322 | 现货 | ||
10 mg | ¥ 461 | 现货 | ||
25 mg | ¥ 795 | 现货 | ||
50 mg | ¥ 1,190 | 现货 | ||
100 mg | ¥ 1,930 | 现货 | ||
500 mg | ¥ 5,250 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 375 | 现货 |
产品描述 | SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/0.22 μM; able to transport through the blood-brain barrier. |
靶点活性 | MEK2:0.22 μM, MEK1:0.18 μM |
体外活性 | 30 mg/Kg SL327明显损害小鼠空间学习记忆.50 mg/kg SL327可以透过血-脑屏障,通过抑制MAPK/ERK磷酸化而抑制条件性恐惧. |
体内活性 | SL327对多种其他包括PKA,PKC或CamKII的激酶没有抑制效果。 |
激酶实验 | The ligand binding competition assays are performed. Cytosolic cell extracts from Hepa-1 cells are generated by the resuspension of the cell pellets in HEDG buffer [25 mM Hepes, 1 mM EDTA, 1 mM dithiothreitol, and 10% (v/v) glycerol, pH 7.5] containing 0.4 mM leupeptin, 4 mg/mL aprotinin, and 0.3 mM phenylmethylsulfonyl fluoride, homogenization, and centrifugation at 100,000 g for 45 min. Aliquots of the supernatant (120 μg) are incubated at room temperature for 2 h with the indicated concentrations of Pifithrin-α in the presence of 3 nM [3H]TCDD in HEDG buffer. After incubation on ice with hydroxyapatite for 30 min, HEDG buffer with 0.5% Tween 80 is added. The samples are centrifuged, washed twice, resuspended in 0.2 mL of scintillation fluid, and subjected to scintillation counting. Nonspecific binding is determined using a 150-fold molar excess of TCDF and subtracted from the total binding to obtain the specific binding. The specific binding is reported relative to [3H]TCDD alone[2]. |
别名 | SL 327, SL-327 |
分子量 | 335.35 |
分子式 | C16H12F3N3S |
CAS No. | 305350-87-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 33.5 mg/mL (100 mM)
Ethanol: 16.8 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.982 mL | 14.9098 mL | 29.8196 mL | 74.549 mL |
5 mM | 0.5964 mL | 2.982 mL | 5.9639 mL | 14.9098 mL | |
10 mM | 0.2982 mL | 1.491 mL | 2.982 mL | 7.4549 mL | |
20 mM | 0.1491 mL | 0.7455 mL | 1.491 mL | 3.7274 mL | |
50 mM | 0.0596 mL | 0.2982 mL | 0.5964 mL | 1.491 mL | |
DMSO | 100 mM | 0.0298 mL | 0.1491 mL | 0.2982 mL | 0.7455 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SL327 305350-87-2 Cell Cycle/Checkpoint DNA Damage/DNA Repair MAPK MEK DNA/RNA Synthesis Mitogen-activated protein kinase kinase inhibit Inhibitor MAPKK SL 327 MAP2K SL-327 inhibitor